Growth Strategy Through Business Development

A robust growth strategy is important to a fast developing specialty biopharmaceutical company. Through strategic in-licensing and productive academic collaborations, ObsEva is building a meaningful clinical portfolio of product candidates around multiple reproductive therapeutic assets that can address significant unmet medical needs for millions of women worldwide.

At ObsEva, our growth strategy includes the acquisition of additional clinical-stage assets, focusing either on new applications for existing drugs, or on new molecular entities that can address unmet needs for our patients. Clinical-stage assets of interest for ObsEva would meet the following Target Product Profile:

  • Women’s reproductive health medicine
  • Small chemical molecules, peptides, proteins, or mAbs
  • Development stage: close to First-In-Man up to end-of-Phase2
  • No generic drugs, unless innovative and proprietary delivery method and/or exclusivity
  • License rights: preferably global

ObsEva’s review process has been designed to provide a rapid assessment of potential opportunities with the early involvement of our leadership. Our evaluation analysis relies on scientific criteria and business potential estimation.

Side Image

Partnering with pharmaceutical companies: Should you represent a pharmaceutical company seeking a strong and committed partner for the development and the commercialization of a potential product, please do not hesitate to send an email to the contact below briefly describing your project.

Collaboration with Kissei Pharmaceutical

In 2015, ObsEva entered into a collaboration agreement with Kissei Pharmaceutical Co., Ltd., a Japanese pharmaceutical company with approximately 70 years of expertise in the fields of obstetrics/gynecology, renal dialysis, urology, metabolism, and ophthalmology.

Under the terms of the agreement, ObsEva acquired the exclusive license to develop and commercialize OBE2109 worldwide (excluding certain Asian countries) for the treatment of endometriosis and other potential indications.

To Partner With Us

ObsEva, CEO office
Chemin des Aulx, 12
CH-1228 Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840